Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multi-center, Randomized, Double-blinded, Placebo-controlled, and Open-label, Active-controlled, Parallel-group Comparative Study to Assess Efficacy and Safety of an Extended Flexible Regimen of BAY 86-5300 [0.02 mg Ethinylestradiol (beta-CDC) and 3 mg Drospirenone] in the Patients With Endometriosis

Next Previous
X
Search
Trial Profile

A Multi-center, Randomized, Double-blinded, Placebo-controlled, and Open-label, Active-controlled, Parallel-group Comparative Study to Assess Efficacy and Safety of an Extended Flexible Regimen of BAY 86-5300 [0.02 mg Ethinylestradiol (beta-CDC) and 3 mg Drospirenone] in the Patients With Endometriosis

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 10 Jan 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Drospirenone/ethinylestradiol (Primary) ; Dienogest
  • Indications Endometriosis
  • Focus Registrational; Therapeutic Use
  • Sponsors Bayer

    • Most Recent Events

    • 11 Sep 2017 Primary endpoint (Change of pelvic pain) has been met, according to the results published in the Fertility and Sterility.
    • 11 Sep 2017 Results published in the Fertility and Sterility
    • 21 Jan 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top